Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bridgepoint announces 'strong' full-year profit

(Sharecast News) - Bridgepoint reported "strong" full-year underlying profit growth, alongside a record amount of capital returned to clients. For his part, chief executive officer Raoul Hughes described the medium-term prospects for private markets "exciting" and reiterated a goal to more than double its assets under management over the coming five to six years to $200bn.

At period end, Bridgepoint's AuM stood at $75.6bn and the fee paying AuM at €38.7bn.

The private equity outfit also reported a 51.9% jump in total pro-forma underlying operating income to reach £542.5m.

That tally included a full year of activity at US infrastructure investor Energy Capital Partners, the acquisition of which closed in August.

Also in pro-forma underlying terms, profit before tax jumped 83.4% to £249.8m.

On a reported basis on the other hand, profit after tax came in at £69.1m, versus £70.7m one year before, for basic earnings per share of 8.0p and 8.7p, respectively.

A record €8.5bn was returned in 2024 to fund investors.

Management added that transaction volumes were increasing and pointed to "good" near-term visibility on several further exits for 2025, two-thirds of which were expected to materialise during the back half of the year.

The 'next cycle' fundraising target was raised from €20bn to €24bn and guided towards an EBITDA margin of 52-55% over 2025/26.

The company proposed a final dividend of 4.6p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.